Catalyst Pharmaceuticals up 18% after resumption following Teva settlement
Shares of Catalyst Pharmaceuticals (CPRX) have resumed trading and are higher after the company announced that the company and its licensor SERB S.A. have entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals (TEVA) that resolves the patent litigation brought by Catalyst and SERB in response to Teva’s Abbreviated New Drug Application for a generic version of Firdapse 10 mg tablets prior to expiration of the applicable patents. Catalyst shares are up $3.60, or 18%, to $23.13 after resuming following a trading halt.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CPRX:
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.